Microbio Co., Ltd.

As of June 30, 2026, Microbio Co., Ltd. carries a market capitalization of 9.44B, placing it among publicly traded companies globally. Its enterprise value stands at 8.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Microbio Co., Ltd. has 588.17M shares outstanding.

As of June 30, 2026, Microbio Co., Ltd. trades at a trailing price-to-earnings ratio of 18.07. The price-to-sales ratio is 4.81, and the price-to-book ratio stands at 0.99.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 8.50B versus a market cap of 9.44B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Microbio Co., Ltd. maintains a current ratio of 6.07, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.64, indicating elevated leverage, while an interest coverage ratio of -14.77 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Microbio Co., Ltd. posted a return on equity (ROE) of 5.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -4.14, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 4.17, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.13, useful for judging operating efficiency across full business cycles. The company generates approximately 3.17M in revenue per employee across its workforce of 620.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.32 indicates how many times Microbio Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Microbio Co., Ltd. recorded 1.96M in income tax expense. That works out to an effective tax rate of 0.74, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 263.36M, leaving 523.23M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Microbio Co., Ltd.'s stock has declined approximately 33.93% over the past 52 weeks. The 50-day moving average sits at 15.00, while the 200-day moving average is 16.38.

Over the twelve months ended June 30, 2026, Microbio Co., Ltd. generated 1.97B in revenue and converted that into 523.23M in net income, yielding earnings per share of 0.44. EBITDA reached -188.96M, while operating income came in at -467.10M.

As of June 30, 2026, Microbio Co., Ltd. holds 2.84B in cash and equivalents against 709.48M in total debt, resulting in a net debt position of -571.23M. Total book value stands at 9.50B, with working capital of 2.78B providing operational flexibility.

Microbio Co., Ltd. produced -193.40M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -57.15M in capital expenditures, free cash flow totaled -250.54M - equivalent to -0.43 per share.

Over the twelve months ended June 30, 2026, Microbio Co., Ltd. posted a gross margin of 39.60, reflecting its pricing power and cost economics. The operating margin of -23.77 and net profit margin of 26.62 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.89, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Microbio Co., Ltd. shareholders.

Microbio Co., Ltd.'s most recent stock split took place on August 29, 2024 with a 20:21 split ratio.

As of June 30, 2026, Microbio Co., Ltd. has an Altman Z-Score of 2.94, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.